Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead Sciences’ already dominant position in ... and showed a subcutaneous injection with lenacapavir every six months was more effective than its widely-used oral PrEP drug Truvada ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

Gilead Sciences has taken a major step towards increasing ... paving the way for increased production and distribution of lenacapavir, its long-acting HIV prevention medication, in 120 high ...

JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...